Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Vaxcyte, Inc. (NASDAQ:PCVX) has received a consensus rating of "Moderate Buy" from eight ratings firms, with one sell, one hold, five buy, and one strong buy recommendation. The average 12-month target price among analysts is $106.25.
• Institutional investors control 96.78% of Vaxcyte's stock, with several firms recently increasing their stakes significantly, including IFP Advisors Inc, which boosted its stake by 376.4%.
• The company's recent earnings report revealed an EPS of ($1.22), missing the consensus estimate of ($1.12) per share, highlighting challenges as Vaxcyte aims to launch its investigational pneumococcal conjugate vaccine, VAX-24.

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $106.25.

PCVX has been the subject of several recent analyst reports. The Goldman Sachs Group initiated coverage on Vaxcyte in a research note on Friday, September 12th. They issued a "neutral" rating and a $38.00 price target for the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Vaxcyte in a research note on Saturday, September 27th. Finally, Cowen reissued a "buy" rating on shares of Vaxcyte in a research note on Thursday, August 7th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PCVX. AlphaQuest LLC bought a new position in Vaxcyte during the first quarter valued at about $33,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Vaxcyte during the first quarter valued at about $35,000. CWM LLC boosted its stake in Vaxcyte by 197.3% during the second quarter. CWM LLC now owns 1,680 shares of the company's stock valued at $55,000 after buying an additional 1,115 shares in the last quarter. IFP Advisors Inc boosted its stake in Vaxcyte by 376.4% during the first quarter. IFP Advisors Inc now owns 1,653 shares of the company's stock valued at $62,000 after buying an additional 1,306 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in Vaxcyte by 176.7% during the second quarter. Blue Trust Inc. now owns 2,161 shares of the company's stock valued at $70,000 after buying an additional 1,380 shares in the last quarter. Institutional investors own 96.78% of the company's stock.

Vaxcyte Stock Performance

NASDAQ:PCVX opened at $41.87 on Wednesday. Vaxcyte has a 1 year low of $27.66 and a 1 year high of $118.62. The stock has a market cap of $5.44 billion, a price-to-earnings ratio of -10.19 and a beta of 1.12. The business has a fifty day moving average of $32.98 and a 200-day moving average of $34.52.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period in the prior year, the company earned ($1.10) earnings per share. On average, equities research analysts predict that Vaxcyte will post -4.21 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.